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Abstract 
Prescottella equi (formerly Rhodococcus equi) is an intracellular pathogen that causes pyogranulomatous 
pneumonia in Thoroughbred foals. There is currently no vaccine available for the prevention of this disease in foals 
despite years of research. Cell mediated immunity is considered crucial for overcoming an infection caused by this 
pathogen. The virulence associated protein (VapA) is a well characterized immunogenic protein associated with this 
pathogen and was used to develop DNA and recombinant protein vaccines in this study. Vaccine candidates and live 
P. equi based vaccine were tested in BALB/c mice. Mice were challenged with virulent P.equi 2 weeks following 
the last boost and IgG subtypes and bacterial clearance from spleen and liver determined. The DNA vaccine elicited 
a significant IgG2a response indicating a Th1 biased immune response. The IFN gamma response from DNA and 
recombinant VapA vaccinated mice was moderate. The results of the challenge study showed that neither the 
recombinant VapA protein nor DNA vaccine enhanced clearance of P. equi in this model.  
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1. Introduction 
Prescottella equi (formerly Rhodococcus equi) is a ubiquitous Gram-positive actinomycete and a significant 
pathogen in foals particularly Thoroughbred foals less than 6 months old. P. equi predominantly causes a 
pyogranulomatous bronchopneumonia in the host and P. equi disease is associated with significant morbidity and 
mortality in horse breeding farms in many parts of the world. 1-3 Virulent isolates of P. equi contain an 80–90 kb 
plasmid which encodes virulence-associated proteins such as the virulence associated protein VapA.4  Over the 
years a number of vaccine candidates, some of these based upon VapA have been developed for the prevention of P.
equi disease in foals. However, none of these vaccines have been transitioned to be commercially available.5-
10Studies conducted using live, virulent P.equi have been shown to be the most effective at inducing significant 
protection against challenge while attenuated P.equi based vaccines have not been shown to be protective.10,11 Due 
to safety issues however live virulent P. equi is not considered to be suitable for development as a vaccine. Studies 
have shown that while both Th1and Th2 immune responses are required to overcoming a P. equi infection, strong 
Th1 type cell mediated responses play an important role in clearing an infection caused by this pathogen .12 
This study, describes the development of DNA and protein vaccines based upon VapA that were tested in the 
murine model and compared with a live virulent P. equi vaccine.  
2. Materials and Methods 
2.1 Construction of vaccines used in this study 
2.1.1 DNA vaccine 
The vapA gene was PCR amplified from P. equi ATCC 33701 using the forward primer 5ƍ-
GAGGATCCATGGAGACTCTTCACAAGACG-3ƍ and reverse primer 5ƍ-
GATGAATTCTAACAACCGAGGCTGAGCG-3ƍ. The forward primer also contained a Kozak sequence CCATGG 
(start codon underlined). The PCR product was cloned into the pcDNA3 vector (Life Technologies, USA) to 
construct plasmid for use as a DNA vaccine. Large-scale plasmid preparations were prepared by standard methods 
and purified  twice by CsCl gradient centrifugation and dialysed twice against TE buffer. Prior to vaccination. 
Endotoxin levels in the vaccine preparations were determined and shown to be less than 10 pg/ml by the QCL-1000 
Limulus Amoebocyte Lysate Kit (BioWhittaker, USA) 
2.1.2.Recombinant VapA vaccine 
The vapA gene was amplified using PCR with the forward primer 5ƍ-
GACCATGGATGGAGACTCTTCACAAGACG-3ƍ and the reverse primer 5ƍ-
GCCTCGAGGGCGTTGTGCCAGCTACC-3ƍ for cloning into the pET-28a (+) (Novagen, USA) expression vector 
to create the construct for recombinant His tagged VapA vaccine preparation. VapA from this construct was 
expressed in E.coli and purified using a previously described method for the production of His-tagged proteins 
(Vanniasinkam et al., 2004).  
2.2Vaccination of mice 
Groups of five 6-8 week old BALB/c mice were injected with 50 Pg of DNA  vaccine (50 Pl volume) into each 
quadriceps muscle, 50 Pg DNA vaccine and 5 Pg murine cytokine IL-12 expressing plasmid pORF-mIL12 
(InvivoGen, USA), 50 Pl aliquot of the VapA protein preparation containing a concentration of 100 Pg protein, 
mixed with an equal volume of 1.3% aluminium hydroxide gel (Alhydrogel, Asia Pacific Specialty Chemicals Ltd, 
NSW, Australia), injected intraperitoneally or 105 live P. equi strain ATCC 33701 administered by the 
intraperitoneal route. Control group was injected with 50 Pg of empty plasmid vector. This study was repeated on 3 
separate occasions. 
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All mice were vaccinated on 3 occasions, 2 weeks apart and bled prior to every boost and just before challenge. 
2.2 Detection of total IgG and subclasses IgG1, IgG2a, IgG2b 
Levels of VapA specific total IgG and IgG subclasses in serum were performed using an ELISA on mouse serum 
diluted 1 in 250 in PBS/0.05% Tween-20 buffer using a previously described method using a His-tagged VapA 
antigen as the coating antigen in this assay.9 Serum from individual mice were pooled prior to use in the assays. 
2.3 Determination of DTH response 
DTH response studies were performed using whole P. equi strain ATCC 33701 antigen preparations as described 
previously.9The right hind footpad of each mouse was injected with 20 ȝl of the antigen and the corresponding left 
hind footpad was injected with 20 ȝl PBS. Footpad thickness was measured at 24, 48 and 72 h intervals using 
Vernier calipers (the average of three readings was obtained). DTH at 24 h was used in all analyses as the reaction 
was most significant at this time compared with the control. Percentage swelling was calculated using the following 
formula: P. equi antigen footpad swelling (mm) – PBS footpad swelling/PBS footpad swelling×100. Experiments 
were repeated on three occasions. 
2.4Challenge studies 
Two weeks following the last immunisation, animals were challenged with an intravenous inoculation of 1.5×107 
virulent P. equi ATCC 33701. Approximately 1.5 x 107 organisms produced mild symptoms of P. equi disease in the 
mice (ruffled coats and dull eyes). This dose was used in all the challenge studies. Bacterial clearance from the 
spleen and liver was determined 48 to 120 hours after challenge. Mice were euthanased by CO2 inhalationfollowed 
by cervical dislocation and the spleen and liver removed. The spleen and liverwere homogenised in PBS using a 
sterile mortar and pestle, and a viable bacterial count was performed on dilutions of the homogenate in PBS (1 in 
102 to 1 in 106 dilutions). The dilutions were plated on horse blood agar and grown at 37 °C for 48 h and the 
colonies were counted. Results were obtained from three separate experiments. 
2.5Statistical analysis of data 
Data were analysed using a Wilcoxon (rank sum) two-sample test with SAS software (SAS Institute, Inc., NC, 
USA). 
 
3. Results 
3.1 IgG response to vaccination 
 
Bothe the DNA and recombinant VapA vaccines elicited a moderate total IgG response. The DNA vaccine unlike 
the recombinant VapA vaccine elicited a significant IgG2a response (and relatively low IgG2b and IgG1) (Table 1). 
This indicates a Th1 biased immune response. The immune response to the recombinant  VapA vaccine was a much 
higher IgG1 response than with the DNA vaccine, possibly indicating a weaker Th1 type bias in immune response 
than that observed with the DNA vaccine. Co-administration of IL-12 did not make a significant difference to the 
immune response generated to the DNA vaccine. IgG1 to Ig2a ratio was greatest at 6 weeks (9.4, 2.5, 0.91, 10.8 for 
DNA, VapA, vector control, live P. equi respectively). This shows that the highest Th1 response was generated by 
the DNA vaccine.  
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Table 1 IgG1, IgG2a and IgG2b  response at 6 weeks following prime 
Vaccine IgG1 (OD 450nm) ± 
standard deviation 
IgG2a (OD 450nm) ± 
standard deviation 
IgG2b 
(OD 450nm) ± 
standard deviation 
DNA vaccine (vapA) 0.035 ± 0.02 0.332 ± 0.007 0.06 ± 0.005 
Plasmid ctrl 0.013 ± .002 0.038 ± 0.02 0.017 ± 0.01 
Recombinant VapA 0.586 ± .01 1.514 ± 0.08 1.35 ± 0.07 
DNA vaccine (vapA) + IL-12 0.274 ± 0.05 0.251± 0.08 0.011 ± 0.003 
Live P. equi 0.019 ± 0.001 0.206 ± 0.02 0.049 ± 0.01 
 
 
3.2 DTH response to vaccination 
DTH responses were measured and showed that the highest DTH response was observed in mice vaccinated with 
the recombinant VapA vaccine (fig 1).  
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Fig. 1 DTH response 6 weeks after prime 
 
3.3Challenge studies 
Neither the protein nor DNA vaccine significantly enhanced clearance of P. equi following challenge unlike the live 
P. equivaccine which showed a twofold reduction in P.equi isolated from the spleen and liver at 72 hours following 
challenge (data not shown). 
4. Discussion and future directions 
 
Based upon the results of this study, of the vaccine candidates tested, the vapA-based DNA 
vaccine elicited the highest Th1 response. However, while a significant Th1response was elicited 
by the DNA vaccine, mice that were administered this vaccine did not show enhance clearance 
of P.equi from the spleen and liver following challenge. Diasappointingly, the co-administration 
of the IL-12 encoding plasmid while increasing the Th1 bias of the immune response did not 
enhance clearance of P. equi.  Plasmid encoded IL-12 has been used by researchers to enhance 
the efficacy of vaccines.13,14 However, in this study IL-12 administration did not significantly 
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improve the efficacy of the vaccine. The lack of protection afforded by the vaccine candidates 
tested, as observed in the challenge studies, may be partly attributed to the model they were 
tested in. Mice have been used as the small model for vaccine studies by P. equi researchers for 
some years; various strains including BALB/c have been used.6,10,11 However,  in relation to 
P.equi vaccine research, even though they are still a  widely used small animal model,  there are 
clearly  some challenges with using mice as they cannot easily be used for the evaluation of 
vaccines as mice are not a model  that closely resembles the natural pulmonary P. equi infection 
in foals. DNA vaccines have been shown to be successful against a range of pathogens, however 
in this study  the DNA vaccine candidate tested was not shown to be protective against 
challenge.15-17The levels of antibodies generated by the DNA and recombinant protein vaccines 
in this study show that these vaccine candidates can potentially be developed further as 
efficacious vaccines as researchers have shown that while cell mediated immune responses are 
important for protection against P. equi  high titres of P.equi specific  antibodies do play a role in  
providing immunity against P. equi induce disease.18,19 
Overall, vaccine development for P. equi has not led to a commercially available vaccine to date 
and approaches such as viral vector based vaccine development are currently being investigated. 
The vaccine candidates developed in this study could potentially be used in heterologous prime 
boost vaccine regimes together with other vaccine modalities in future studies.   
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